0.2% Chx Gel vs Implant Bacterial Contamination
Launched by G. D'ANNUNZIO UNIVERSITY · Feb 12, 2018
Trial Information
Current as of September 11, 2025
Unknown status
Keywords
ClinConnect Summary
The objective of this human randomized, double blind, placebo-control (RDBPC) study is to evaluate the efficacy of a 0.2% chlorhexidine (CHX) gel on reducing bacterial load and peri-implant inflammation at implant-abutment interface during the early healing stage. Thirty-six healthy patients (mean age 52,28 years; range 29-75 years) without a significant past medical anamnesis, all non-smokers, will be recruited as candidates for single implant placement and prosthetic rehabilitation.Patients will be randomly divided in group A (control) and group B (test) as indicated by the randomization ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients of both sex between 18 and 75 years,
- • good systemic and oral health,
- • need of single crown implant supported restoration,
- • at least six months of healing after tooth extraction,
- • cortical bone thickness \> 5 mm measured by means of a cone beam computed tomography (CBCT).
- Exclusion Criteria:
- • poor oral hygiene,
- • active periodontal disease or other oral disorders,
- • insufficient bone thickness for implant insertion,
- • bone augmentation procedures,
- • immediate loading protocols,
- • uncontrolled diabetes mellitus,
- • immune diseases,
- • smoking
- • bruxism.
About G. D'annunzio University
G. D'Annunzio University, located in Chieti-Pescara, Italy, is a prominent academic institution committed to advancing scientific research and innovation in the health sciences. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment that encourages the development of novel therapeutic strategies and clinical applications. As a clinical trial sponsor, G. D'Annunzio University seeks to contribute to the improvement of patient outcomes through rigorous research methodologies, ethical standards, and a focus on translational medicine. Their dedication to education and research excellence positions them as a key player in the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chieti, Ch, Italy
Patients applied
Trial Officials
Sergio caputi, MD, DDS
Principal Investigator
g. d'annunzio chieti-pescara university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials